Markets, capital, and the discipline of patient investing.
RFC Capital Research publishes the independent analysis of Ruslan Averin — an investor focused on public markets, sovereign and corporate fixed income, cross-border real estate, and capital allocation across emerging and frontier markets.
No institutional mandate, no house view to defend — a working record of how one investor thinks about risk, value, and the markets most analysts avoid.
Adobe Beat Earnings and Still Sank 10% — Here's What Spooked the Tape
Ruslan Averin's ADBE stock analysis: Adobe topped Q2 estimates and raised guidance, yet shares fell as much as 10% on June 12 after the CFO walked.
MarketsChevron (CVX) Dropped Again as Hormuz Reopens — The Oil-Leverage Trade Ahead of the Fed
Ruslan Averin's NYSE:CVX stock analysis: Chevron fell 3.76% as WTI sank over 5% on the U.S.–Iran deal, just as markets eyed the June FOMC.
MarketsExxon (XOM) Fell as Oil Slid on a Peace Deal — Why I'm Not Buying the Dip Yet
Ruslan Averin's NYSE:XOM stock analysis: Exxon slid 3.46% to about $141.77 as crude collapsed on the U.S.–Iran peace deal that reopens Hormuz.
AnalysisLockheed Martin (LMT) Slid on the Peace Deal — Why I Think the War Premium Is Leaving
Ruslan Averin's NYSE:LMT stock analysis: Lockheed slid as a U.S.–Iran peace deal priced out the war premium, with defense down across the board.
MarketsNeumora Cratered 47% When Its Depression Drug Failed Twice
Ruslan Averin's NMRA stock analysis: Neumora collapsed about 47% on June 15 after Phase 3 KOASTAL navacaprant trials missed in major depression.
AnalysisNorthrop Grumman (NOC) Fell as Iran Risk Faded — The Defense Trade I'm Re-Rating
Ruslan Averin's NYSE:NOC stock analysis: Northrop fell about 1.3% as Trump paused Iran strikes and a peace deal drained the defense war premium.